"At this point we are not recommending any clinical changes to the approach in treating patients," Fukuda said. According to Reuters, all patients confirmed to have Tamiflu-resistant H1N1 have been responsive to the antiviral Relenza and have since recovered from their infection (7/7).

This article is republished with kind permission from our friends at The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Health Policy Report is published for Kaisernetwork, a free service of The Henry J. Kaiser Family Foundation. 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.